BGT226
CAS No. | 1245537-68-1 | Cat. No. | BCP03599 |
Name | BGT226 | ||
Synonyms | NVP-BGT226;NVP-BGT 226;NVP BGT 226; BGT 226; BGT-226; | ||
Formula | C28H25F3N6O2.C4H4O4 | M. Wt | 650.6 |
Description | In a xenografted animal model, NVP-BGT226 significantly delays tumor growth in a dose-dependent manner, along with suppressed cytoplasmic expression of p-p70 S6 kinase and the presence of autophagosome formation. NVP-BGT226 inhibits tumor growth in a dose-dependent manner in a FaDu cell xenografted mouse model. Oral administration of NVP-BGT226 at 2.5 and 5 mg/kg for 3 weeks causes 34.7% and 76.1% reduction of the tumor growth on day 21, respectively (compared with control). NVP-BGT226 displays comparable inhibition against tumor growth to rapamycin. The final volume of both groups is significantly smaller than those treated with LY294002 (a PI3K inhibitor) or the control. | ||
Pathways | PI3K/Akt/mTOR | ||
Targets | PI3K mTOR |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.